Risk factors for nephrotoxicity after ifosfamide treatment in children: A UKCCSG Late Effects Group study

British Journal of Cancer

Volumn 82, Issue 10, 2000, Pages 1636-1645

  Skinner, R ^a   Cotterill, S J ^a   Stevens, M C G ^b  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

^b BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Adolescents; Cancer; Children; Ifosfamide; Nephrotoxicity

Indexed keywords

BICARBONATE; IFOSFAMIDE; PHOSPHATE;

ADOLESCENT; ADULT; ARTICLE; BICARBONATE BLOOD LEVEL; CHILD; DOSE RESPONSE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INFANT; KIDNEY TUBULE; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RISK FACTOR; SARCOMA;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IFOSFAMIDE; INFANT; KIDNEY; KIDNEY GLOMERULUS; KIDNEY TUBULES; MALE; NEUROECTODERMAL TUMORS, PRIMITIVE; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RHABDOMYOSARCOMA;

EID: 0034014698     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. 2 of ifosfamide. Cancer Chemother Pharmacol 34: 431-433
2. Ashraf MS, Brady J, Breatnach F, Deasy PF and O'Meara A (1994) Ifosfamide nephrotoxicity in paediatric cancer patients. Eur J Paediatr 153: 90-94
3. Ashraf MS, Skinner R, English MW, Craft AW and Pearson ADJ (1997) Late reversibility of chronic ifosfamide-associated nephrotoxicity in a child. Med Pediatr Oncol 28: 62-64
4. Barratt TM (1974) Assessment of renal function in children. In: Modern Trends in Paediatrics, 4. Apley J (ed), pp. 181-215. Butterworth, London
5. Barratt TM, McLaine PN and Soothill JF (1970) Albumin excretion as a measure of glomerular dysfunction in children. Arch Dis Child 45: 496-501
6. Biron P, Philip T, Pinkerton R, Provensal C and Brunat-Mentigny M (1987) A regimen with ifosfamide and cis-platinum in osteosarcomas: a phase-II study. Contrib Oncol 26: 125-130
7. Bisogno G, Dussini N, Moggia D, Perilongo G and Carli M (1993) Pattern of aminoaciduria in patients with soft-tissue sarcomas treated with ifosfamide-containing regimens. Am J Pediatr Hematol Oncol 15: S5-S9
8. Bleyer WA (1990) The impact of childhood cancer on the United States and the world. Ca: Cancer J Clin 40: 355-367
9. Boddy AV, English MW, Pearson ADJ, Idle JR and Skinner R (1996) Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics. Eur J Cancer 32A: 1179-1184
10. Bremner DN, McCormick JS and Thomson JWW (1974) Clinical trial of isophosphamide (NSC-109724) - results and side effects. Cancer Chemother Rep 58: 889-893
11. Brodehl J, Gellison K and Weber HP (1982) Postnatal development of tubular phosphate reabsorption. Clin Nephrol 17: 163-171
12. Burk CD, Restaino I, Kaplan BS and Meadows AT (1990) Ifosfamide-induced renal tubular dysfunction and rickets in children with Wilms tumor. J Pediatr 117: 331-335
13. Caron HN, Abeling N, van Gennip A, de Kraker J and Voute PA (1992) Hyperaminoaciduria identifies patients at risk of developing renal tubular toxicity associated with ifosfamide and platinate containing regimens. Med Pediatr Oncol 20: 42-47
14. Clayton BE, Jenkins P and Round JM (1980) Paediatric Chemical Pathology. Blackwell Scientific, Oxford
15. Craft A, Cotterill S, Malcolm A, Spooner D, Grimer R, Souhami R, Imeson J and Lewis I (1998) Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. J Clin Oncol 16: 3628-3633
16. Davies SM, Pearson ADJ and Craft AW (1989) Toxicity of high-dose ifosfamide in children. Cancer Chemother Pharmacol 24: S8-S10
17. de Kraker J and Voute PA (1984) Ifosfamide and vincristine in paediatric tumours. A phase II study. Eur Paediatr Haematol Oncol 1: 47-50
18. De Schepper J, Stevens G, Verboven M, Baeta C and Otten J (1991) Ifosfamide-induced Fanconi's syndrome with growth failure in a 2-year-old child. Am J Pediatr Hematol Oncol 13: 39-11
19. De Schepper J, Hachimi-Idrissi S, Verboven M, Piepsy A and Otten J (1993) Renal function abnormalities after ifosfamide treatment in children. Acta Paediatr 82: 373-376
20. Demeocq F, Oberlin O, Benz-Lemoine E, Biolletot A, Gentet JC, Zucker JM, Behar C, Poutard P, Olive D, Brunat-Mentigny M, Demaille MC, Patte C, Contesso G and Lemerle J (1989) Initial chemotherapy including ifosfamide in the management of Ewing's sarcoma: preliminary results. A protocol of the French Pediatric Oncology Society (SFOP). Cancer Chemother Pharmacol 24: S45-S47
21. Devalek C, Ismaili K, Ferster A and Saribou E (1991) Acute ifosfamide-induced proximal tubular toxic reaction (letter). J Pediatr 118: 325-326
22. Elises JS, Griffiths PD, Hocking MD, Taylor CM and White RHR (1988) Simplified quantification of urinary protein excretion in children. Clin Nephrol 30: 225-229
23. Fetterman GH, Shuplock NA, Philipp FJ and Gregg HS (1965) The growth and maturation of human glomeruli and proximal convolutions from term to adulthood. Pediatr 35: 601-619
24. Gasparini M (1986) High dose ifosfamide alone and in combination for solid malignancies in childhood. Cancer Chemother Pharmacol 18: S18
25. Grantham JJ and Chonko AM (1991) Renal handling of organic anions and cations; excretion of uric acid. In: The Kidney, Brenner BM and Rector FC Jr (eds), Vol. I, pp. 483-509. WB Saunders, Philadelphia
26. Hawkins MM and Stevens MCG (1996) The long-term survivors. Br Med Bull 52: 898-923
27. Heney D, Lewis IJ and Bailey CC (1989) Acute ifosfamide-induced tubular toxicity (letter). Lancet ii: 103-104
28. Holoye PY, Anderson T, Duelge J, Hansen RM and Ritch PS (1982) Use and safety of high-dose ifosfamide. Semin Oncol 9: 78-86
29. Kellie SJ, de Kraker J, Lilleyman JS, Bowman A and Pritchard J (1988) Ifosfamide in previously untreated disseminated neuroblastoma. Eur J Cancer Clin Oncol 24: 903-908
30. Moncrieff M and Foot A (1989) Fanconi syndrome after ifosfamide. Cancer Chemother Pharmacol 23: 121-122
31. Prasad VK, Lewis IJ, Aparicio SR, Heney D, Hale JP, Bailey CC and Kinsey SE (1996) Progressive glomerular toxicity of ifosfamide in children. Med Pediatr Oncol 27: 149-155
32. Pratt CB, Douglass EC, Etcubanas EL, Goren MP, Green AA, Hayes FA, Horowitz ME, Meyer WH, Thompson EI and Wilimas JA (1989) Ifosfamide in pediatric malignant solid tumors. Cancer Chemother Pharmacol 24: S24-S27
33. Pratt CB, Meyer WH, Jenkins JJ, Avery L, McKay CP, Wyatt RJ and Hancock ML (1991) Ifosfamide, Fanconi's syndrome, and rickets. J Clin Oncol 9: 1495-1499
34. Raney B, Ensign LG, Foreman J, Khan F, Newton W, Ortega J, Ragab A, Wharam M, Wiener E and Maurer H (1994) Renal toxicity of ifosfamide in pilot regimens of the Intergroup Rhabdomyosarcoma Study for patients with gross residual disease. Am J Pediatr Hematol Oncol 16: 286-295
35. Rossi R, Godde A, Kleinebrand A, Riepenhausen M, Boos J, Ritter J and Jurgens H (1994) Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients. J Clin Oncol 12: 159-165
36. Sangster G, Kaye SB, Calman KC and Dalton JF (1984) Failure of 2-mercaptoethane sulphonate sodium (mesna) to protect against ifosfamide nephrotoxicity. Eur J Cancer Clin Oncol 20: 435-436
37. Shaw PJ and Eden OB (1990) Ifosfamide in paediatric oncology: tried but not tested? Lancet i: 1022-1023
38. Shore R, Greenberg M, Geary D and Koren G (1992) Iphosphamide-induced nephrotoxicity in children. Pediatr Nephrol 6: 162-165
39. Skinner R, Pearson ADJ, Price L, Coulthard MG and Craft AW (1990) Nephrotoxicity after ifosfamide. Arch Dis Child 65: 732-738
40. Skinner R, Pearson ADJ, Coulthard MG, Skillen AW, Hodson AW, Goldfinch ME, Gibb I and Craft AW (1991) Assessment of chemotherapy-associated nephrotoxicity in children with cancer. Cancer Chemother Pharmacol 28: 81-92
41. Skinner R, Sharkey IM, Pearson ADJ and Craft AW (1993) Ifosfamide, mesna and nephrotoxicity in children. J Clin Oncol 11: 173-190
42. Skinner R, Pearson ADJ, Price L, Wyliie RA, English MW, Hodson AW, Skillen AW, Coulthard MG and Craft AW (1994) Ifosfamide nephrotoxicity in children: early detection and prediction of severity (abstract). Med Pediatr Oncol 23: 178
43. Skinner R, Pearson ADJ, English MW, Price L, Wyllie RA, Coulthard MG and Craft AW (1996) Chronic ifosfamide nephrotoxicity in children. Lancet 348: 578-580
44. Smeitink J, Verreussel M, Schroder C and Lippens R (1988) Nephrotoxicity associated with ifosfamide. Eur J Pediatr 148: 164-166
45. StataCorp (1997) Stata Statistical Software: Release 5.0. Stata Corporation College Station, TX
46. Suarez A, McDowell H, Niaudet P, Comay E and Flamant F (1991) Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report. J Clin Oncol 9: 2177-2182
47. Task Force on Blood Pressure Control in Children (1987) Report of the Second Task Force on Blood Pressure Control in Children - 1987. Pediatrics 79: 1-25
48. Van Gool S, Brock P, Wijndaele G, Van de Casseye W, Kruger M, Proesmans W and Casteels-Van Daele M (1992) Reversible hypophosphatemic rickets following ifosfamide treatment. Med Pediatr Oncol 20: 254-257
49. Wheeler BM, Loehrer PJ, Williams SD and Einhorn LH (1986) Ifosfamide in refractory male germ cell tumours. J Clin Oncol 4: 28-34
50. Zalupski M and Baker LH (1988) Ifosfamide. J Natl Cancer Inst 80: 556-566